Sugi Predict

Sugi Predict / Targets / MGAM2

MGAM2

Probable maltase-glucoamylase 2 (Maltase-gluc · Q2M2H8 · MGAM2 on Sugi Atlas →

64,526 patent compounds predicted against MGAM2, 35,761 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL110724 SCHEMBL110724 0.53 15/20
SCHEMBL159015 SCHEMBL159015 0.52 15/20
SCHEMBL170673 SCHEMBL170673 0.71 9/20
SCHEMBL202954 SCHEMBL202954 0.54 9/20
SCHEMBL124191 SCHEMBL124191 0.59 7/20
SCHEMBL108954 SCHEMBL108954 0.57 7/20
SCHEMBL45441 SCHEMBL45441 0.64 6/20
SCHEMBL37609 SCHEMBL37609 0.48 6/20
SCHEMBL230979 SCHEMBL230979 0.48 6/20
SCHEMBL37608 SCHEMBL37608 0.47 6/20
SCHEMBL37629 SCHEMBL37629 0.45 6/20
SCHEMBL94134 SCHEMBL94134 0.60 5/20
SCHEMBL204056 SCHEMBL204056 0.54 5/20
SCHEMBL240665 SCHEMBL240665 0.54 5/20
SCHEMBL148211 SCHEMBL148211 0.52 5/20
SCHEMBL56853 SCHEMBL56853 0.55 4/20
1-Hydroxy-4-Propoxybenzene 1-Hydroxy-4-Propoxybenzene (SCHEMBL56796) 0.51 4/20
SCHEMBL69679 SCHEMBL69679 0.49 4/20
SCHEMBL205626 SCHEMBL205626 0.49 4/20
SCHEMBL5938 SCHEMBL5938 0.49 4/20

Clinical trials — most relevant to MGAM2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment PHASE4COMPLETED
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG PHASE2/PHASE3ACTIVE_NOT_RECRUITING
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease PHASE3COMPLETED
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) PHASE2/PHASE3COMPLETED
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa PHASE3ACTIVE_NOT_RECRUITING
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. PHASE3COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients PHASE2ENROLLING_BY_INVITATION
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG PHASE2COMPLETED
Biomarker for Glycogen Storage Diseases (BioGlycogen) nanWITHDRAWN
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia nanUNKNOWN
Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E nanCOMPLETED
An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica- nanUNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Glycosade v UCCS in the Dietary Management of Hepatic GSD nanCOMPLETED
BMN 110 US Expanded Access Program nanAPPROVED_FOR_MARKETING
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
Effect of an Polyphenolic Beverage in Healthy Volunteers nanACTIVE_NOT_RECRUITING
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis nanNOT_YET_RECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Higher Dose of Alglucosidase Alpha for Pompe Disease nanNOT_YET_RECRUITING
Predisposition Genes in Monogenic Diabetes (DIAMONO) nanCOMPLETED
'Glycogen Storage Diseases (GSDs) in Indian Children- Establishing an Indian GSD (I-GSD) Registry' nanRECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Pregnancy and Birth Outcome in Women With Pompe Disease nanCOMPLETED
Limb Girdle Muscular Dystrophy Type 2E Recruitment Study nanUNKNOWN
Microbial Enzyme Impact on Postprandial Nutrient Levels and Gastrointestinal Symptoms in Healthy Adults nanCOMPLETED
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a MGAM2 binder may also engage these)

ProteinNameSimilarity
O04931 — 0.998 O04931 →
MGAM Maltase-glucoamylase 0.998 landscape →
Q92442 — 0.997 Q92442 →
P23739 — 0.995 P23739 →
SI Sucrase-isomaltase, intestinal 0.995 landscape →
P07768 — 0.994 P07768 →
P28843 — 0.993 P28843 →
Q93324 — 0.992 Q93324 →
O62653 — 0.992 O62653 →
Q9VTJ4 — 0.992 Q9VTJ4 →
Q86M34 — 0.991 Q86M34 →
Q5IS50 — 0.991 Q5IS50 →
Q9Z218 — 0.990 Q9Z218 →
Q9US55 — 0.990 Q9US55 →
F4J6T7 — 0.989 F4J6T7 →
P23780 — 0.989 P23780 →
Q64319 — 0.989 Q64319 →
P23613 — 0.989 P23613 →
Q91WV7 — 0.989 Q91WV7 →
Q09840 — 0.989 Q09840 →
Q60HF6 — 0.989 Q60HF6 →
GLB1 Beta-galactosidase 0.989 landscape →
P70699 — 0.988 P70699 →
Q67VU7 — 0.988 Q67VU7 →
P29064 — 0.988 P29064 →
Q8VZR2 — 0.988 Q8VZR2 →
Q22492 — 0.988 Q22492 →
O16171 — 0.988 O16171 →
Q95WY5 — 0.988 Q95WY5 →
Q5GRG2 — 0.988 Q5GRG2 →